Exclusives

A 300-patient RCT will evaluate a switchable acrylic adhesive drape, Comfort Release NPWT, vs the VAC Drape for safe removal in NPWT with the primary outcome of incidence of skin injury, pain, stress, and drape integrity from removal up to 8...

PolyNovo has recently moved into the plastic surgery space with the launch of NovoSorb MPX, which it feels could be a bigger opportunity than NovoSorb BTM used for trauma and burn. It's also looking to enter the podiatry space for DFUs and...

Coloplast divested its core Skin Care business as part of a strategic initiative to simplify business operations and improve profitability in the Advanced Wound Care business area. The transaction was completed on Dec 3, 2024, with the...

Legacy Medical has withdrawn a 120-patient RCT initially submitted in May 2024 to demonstrate the clinical utility of its amniotic membrane allograft (Orion) for DFU wound management. clinicaltrials.gov

PolarityBio announces interim enrollment was achieved in SkinTE Phase III pivotal study for treatment of DFUs with complete enrollment expected in H125. The company is also pursuing the first of 2 pivotal studies on SkinTE needed to support a...

A 36-patient study comparing outcomes after fat grafting combined with split-thickness skin grafts (STSGs) and STSGs alone in patients with chronic non-healing wounds found that healing in the fat graft group with STSGs was significantly...

Inotec AMD announced a $33.0MM Series C financing round. The funds will be used to attempt to secure US national reimbursement for Natrox, expand the company’s leadership team, and strengthen global capabilities to drive future growth and...

StimLabs announced it has entered into an exclusive national distribution agreement with Geistlich to commercialize Medicare-approved Derma-Gide, a porcine-derived matrix. The partnership broadens StimLabs' portfolio to include xenografts for...

In its Q324 results, MediWound stated that the phase III study of EscharEx for VLUs is set to commence, with FDA IND submission planned by year-end. The company has also passed the required EMA inspection in preparation for the trial.

A 229-patient study evaluating the clinical efficacy and potential cost-savings associated with ciNPWT in high-risk patients receiving posterior instrumented spinal fusion found ciNPWT is a cost-effective means of reducing rates of wound...